299 related articles for article (PubMed ID: 19177255)
1. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC;
Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255
[TBL] [Abstract][Full Text] [Related]
2. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
[TBL] [Abstract][Full Text] [Related]
3. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
[TBL] [Abstract][Full Text] [Related]
4. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy.
Dören M; Rübig A; Coelingh Bennink HJ; Holzgreve W
Menopause; 1999; 6(4):299-306. PubMed ID: 10614676
[TBL] [Abstract][Full Text] [Related]
5. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
6. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial.
Nijland EA; Weijmar Schultz WC; Nathorst-Boös J; Helmond FA; Van Lunsen RH; Palacios S; Norman RJ; Mulder RJ; Davis SR;
J Sex Med; 2008 Mar; 5(3):646-56. PubMed ID: 18304284
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
8. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
[TBL] [Abstract][Full Text] [Related]
9. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
[TBL] [Abstract][Full Text] [Related]
10. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.
Plumb JM; Guest JF
Pharmacoeconomics; 2000 Nov; 18(5):477-86. PubMed ID: 11151401
[TBL] [Abstract][Full Text] [Related]
12. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
[TBL] [Abstract][Full Text] [Related]
13. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
Samsioe G; Hruska J;
Climacteric; 2010 Feb; 13(1):34-44. PubMed ID: 20001563
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss.
Roux C; Pelissier C; Fechtenbaum J; Loiseau-Peres S; Benhamou CL
Osteoporos Int; 2002 Mar; 13(3):241-8. PubMed ID: 11991445
[TBL] [Abstract][Full Text] [Related]
15. Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo.
Lundström E; Hirschberg AL; Söderqvist G
Maturitas; 2011 Dec; 70(4):361-4. PubMed ID: 21958943
[TBL] [Abstract][Full Text] [Related]
16. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
17. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
18. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels--an association with mammographic density.
Hofling M; Carlström K; Svane G; Azavedo E; Kloosterboer H; Von Schoultz B
Gynecol Endocrinol; 2005 Feb; 20(2):110-5. PubMed ID: 15823831
[TBL] [Abstract][Full Text] [Related]
19. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
[TBL] [Abstract][Full Text] [Related]
20. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
Junge W; El-Samalouti V; Gerlinger C; Schaefers M
Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
